Swaminathan Srividya, Haribabu Jebiti, Karvembu Ramasamy
Center for Computational Modelling, Chennai Institute of Technology, Chennai, Tamil Nadu, 600069, India.
Inorganic and Physical Chemistry Laboratory, CSIR-CLRI, Chennai, Tamil Nadu, 600020, India.
ChemMedChem. 2024 Dec 2;19(23):e202400435. doi: 10.1002/cmdc.202400435. Epub 2024 Oct 7.
The evolution of chemotherapy, especially the dawn of metal-based drugs, represents a transformative era in cancer treatment. From the serendipitous discovery of mustard gas's cytotoxic effects to the sophisticated development of targeted therapies, chemotherapy has significantly refined. Central to this progression is the incorporation of metal-based compounds, such as platinum (Pt), ruthenium (Ru), and gold (Au), which offer unique mechanisms of action, distinguishing them from organic therapeutics. Among these, Ru complexes, exemplified by BOLD-100 and TLD1433, have shown exceptional promise due to their selective activity, lower propensity for resistance, and the ability to target spescific cellular pathways. This paper explores the journey of such Ru candidates, focusing on the mechanisms, efficacy, and clinical potential of these Ru-based drugs, which stand at the forefront of current research, aiming to provide more targeted, less toxic, and highly effective cancer treatments.
化疗的发展，尤其是金属基药物的出现，代表了癌症治疗领域的一个变革性时代。从芥子气细胞毒性作用的偶然发现到靶向治疗的精细发展，化疗有了显著的改进。这一进展的核心是引入了金属基化合物，如铂（Pt）、钌（Ru）和金（Au），它们具有独特的作用机制，与有机治疗药物有所不同。其中，以BOLD-100和TLD1433为代表的钌配合物，因其选择性活性、较低的耐药倾向以及靶向特定细胞途径的能力而展现出非凡的前景。本文探讨了这类钌候选药物的发展历程，重点关注这些基于钌的药物的作用机制、疗效和临床潜力，它们处于当前研究的前沿，旨在提供更具针对性、毒性更低且高效的癌症治疗方法。
